These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27655335)

  • 1. A fluorescent probe assay (Heparin Red) for direct detection of heparins in human plasma.
    Warttinger U; Giese C; Harenberg J; Holmer E; Krämer R
    Anal Bioanal Chem; 2016 Nov; 408(28):8241-8251. PubMed ID: 27655335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of factor IXa inhibition by antithrombin in the presence of unfractionated and low molecular weight heparins and fucoidan.
    Mauray S; de Raucourt E; Talbot JC; Dachary-Prigent J; Jozefowicz M; Fischer AM
    Biochim Biophys Acta; 1998 Sep; 1387(1-2):184-94. PubMed ID: 9748565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays.
    Harris LF; O'Brien A; Castro-López V; O'Donnell JS; Killard AJ
    Thromb Res; 2011 Dec; 128(6):e166-70. PubMed ID: 21872908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Fluorescent Probe for Glycosaminoglycans Applied to the Detection of Dermatan Sulfate by a Mix-and-Read Assay.
    Rappold M; Warttinger U; Krämer R
    Molecules; 2017 May; 22(5):. PubMed ID: 28486420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins.
    Young E; Cosmi B; Weitz J; Hirsh J
    Thromb Haemost; 1993 Oct; 70(4):625-30. PubMed ID: 8115988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
    Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
    Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins.
    Harris LF; Castro-López V; Hammadi N; O'Donnell JS; Killard AJ
    Talanta; 2010 Jun; 81(4-5):1725-30. PubMed ID: 20441964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semisynthesis and analysis of lipophilically modified unfractionated and low molecular mass heparins.
    Malsch R; Harenberg J; Guerrini M; Torri G; Casu B; Heene DL
    Semin Thromb Hemost; 1994; 20(2):182-92. PubMed ID: 7997890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The new heparins].
    Samama M
    Presse Med; 1986 Sep; 15(32):1631-5. PubMed ID: 2949211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL
    Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a rapid and sensitive chromogenic heparin assay for clinical use.
    Wagenvoord RJ; Hendrix HH; Kolde HJ; Hemker HC
    Haemostasis; 1993; 23(1):26-37. PubMed ID: 8477906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of immobilised unfractionated and LMW heparins with proteins in whole human plasma.
    Zammit A; Pepper DS; Dawes J
    Thromb Haemost; 1993 Dec; 70(6):951-8. PubMed ID: 8165617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assessment of anti-factor Xa activity for heparin and related products by chromogenic assays and thrombin generation tests].
    Suzuki A; Kaneko M; Kanno N; Yatomi Y
    Rinsho Byori; 2013 Jul; 61(7):567-75. PubMed ID: 24205696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fluorescent probe for the quantification of heparin in clinical samples with minimal matrix interference.
    Szelke H; Schübel S; Harenberg J; Krämer R
    Chem Commun (Camb); 2010 Mar; 46(10):1667-9. PubMed ID: 20177610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo characterization of a reversible synthetic heparin analog.
    Whelihan MF; Cooley B; Xu Y; Pawlinski R; Liu J; Key NS
    Thromb Res; 2016 Feb; 138():121-129. PubMed ID: 26709038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative evaluation of unfractionated and low molecular weight heparins. Results of the French Etalonorme interlaboratory quality control].
    Houbouyan LL; Goguel AF
    Ann Biol Clin (Paris); 1993; 51(2):109-17. PubMed ID: 8214808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conventional chromogenic heparin assays are influenced by patient's endogenous plasma Antithrombin levels.
    Mitchell LG; Vegh P
    Klin Padiatr; 2010 May; 222(3):164-7. PubMed ID: 20514621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.